Concetta Rafaniello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5797277/publications.pdf

Version: 2024-02-01

279798 214800 2,338 57 23 citations h-index papers

47 g-index 57 57 57 4361 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opinion on Drug Safety, 2014, 13, 57-68.	2.4	588
2	Current pharmacological treatments for COVIDâ€19: What's next?. British Journal of Pharmacology, 2020, 177, 4813-4824.	5.4	210
3	Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine, 2013, 44, 634-647.	2.3	152
4	Metabolic syndrome and postmenopausal breast cancer. Menopause, 2013, 20, 1301-1309.	2.0	110
5	SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment. International Immunopharmacology, 2020, 84, 106519.	3.8	88
6	Effects of ranolazine in a model of doxorubicinâ€induced left ventricle diastolic dysfunction. British Journal of Pharmacology, 2017, 174, 3696-3712.	5.4	73
7	Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases. Drug Safety, 2016, 39, 401-407.	3.2	62
8	Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drugâ€induced liver injury case–control study in Italy. British Journal of Clinical Pharmacology, 2016, 82, 238-248.	2.4	59
9	Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacological Research, 2016, 104, 108-114.	7.1	52
10	The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics Journal, 2018, 18, 422-430.	2.0	47
11	Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opinion on Drug Safety, 2017, 16, 1359-1371.	2.4	41
12	Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. Diabetes Research and Clinical Practice, 2015, 108, 157-163.	2.8	39
13	Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. Expert Opinion on Drug Safety, 2014, 13, 21-29.	2.4	38
14	Pattern of Statin Use in Southern Italian Primary Care: Can Prescription Databases Be Used for Monitoring Long-Term Adherence to the Treatment?. PLoS ONE, 2014, 9, e102146.	2.5	38
15	Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs. Expert Opinion on Drug Safety, 2016, 15, 9-15.	2.4	36
16	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. Frontiers in Cardiovascular Medicine, 2020, 7, 143.	2.4	35
17	Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions. Frontiers in Pharmacology, 2017, 8, 305.	3.5	33
18	Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. Frontiers in Pharmacology, 2017, 8, 607.	3.5	33

#	Article	IF	CITATIONS
19	Drug use and upper gastrointestinal complications in children: a case-control study. Archives of Disease in Childhood, 2013, 98, 218-221.	1.9	32
20	Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions. Expert Opinion on Drug Safety, 2016, 15, 51-59.	2.4	30
21	Safety of Attention-Deficit/Hyperactivity Disorder Medications in Children: An Intensive Pharmacosurveillance Monitoring Study. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 415-422.	1.3	28
22	Effects of chronic treatment with the new ultraâ€longâ€acting <scp>β</scp> ₂ â€adrenoceptor agonist indacaterol alone or in combination with the <scp>β</scp> ₁ â€adrenoceptor blocker metoprolol on cardiac <scp>remodelling</scp> . British Journal of Pharmacology, 2015, 172, 3627-3637.	5.4	28
23	Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System. Pharmaceuticals, 2021, 14, 611.	3.8	28
24	New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety, 2016, 15, 85-100.	2.4	27
25	PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. Drug Safety, 2021, 44, 337-349.	3.2	26
26	Vitamin D Deficiency in Type 2 Diabetic Patients with Hypogonadism. Journal of Sexual Medicine, 2014, 11, 536-542.	0.6	24
27	Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. Drugs - Real World Outcomes, 2020, 7, 41-51.	1.6	23
28	Rational use of antibiotics for the management of children's respiratory tract infections in the ambulatory setting: an evidence-based consensus by the Italian Society of Preventive and Social Pediatrics. Paediatric Respiratory Reviews, 2014, 15, 231-236.	1.8	22
29	Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric ADRs: A Pharmacovigilance Study Based on Data From the Italian Spontaneous Reporting System. Frontiers in Pharmacology, 2020, 11 , 428.	3.5	22
30	Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. European Journal of Clinical Pharmacology, 2016, 72, 285-293.	1.9	21
31	Strengths, weaknesses and future challenges of biosimilars' development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice. Pharmacological Research, 2017, 126, 138-142.	7.1	21
32	Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Frontiers in Pharmacology, 2020, 11, 830.	3.5	21
33	Second generation antipsychotics in â€ [~] real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opinion on Drug Safety, 2016, 15, 1-8.	2.4	20
34	The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. International Journal of Cardiology, 2016, 202, 731-735.	1.7	19
35	Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization's Reporting? A Pharmacovigilance Study in Southern Italy. Frontiers in Pharmacology, 2018, 9, 1003.	3.5	17
36	Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation. Expert Opinion on Drug Safety, 2014, 13, 69-78.	2.4	16

#	Article	IF	CITATIONS
37	Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy. European Journal of Clinical Pharmacology, 2014, 70, 187-195.	1.9	16
38	Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors. Frontiers in Pharmacology, 2018, 9, 611.	3.5	16
39	Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System. Frontiers in Pharmacology, 2019, 10, 425.	3.5	14
40	Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 133-140.	1.3	14
41	Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients. Journal of Clinical Psychiatry, 2016, 77, e1601-e1609.	2.2	14
42	Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system?. Expert Opinion on Drug Safety, 2018, 17, 457-465.	2.4	12
43	Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy. Expert Opinion on Drug Safety, 2019, 18, 427-433.	2.4	12
44	Effects of chronic administration of \hat{l}^2 -blockers on airway responsiveness in a murine model of heart failure. Pulmonary Pharmacology and Therapeutics, 2014, 28, 109-113.	2.6	11
45	We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database. Frontiers in Psychiatry, 2020, 11, 550201.	2.6	10
46	Bisphosphonate-related osteonecrosis of the jaw: an Italian post-marketing surveillance analysis. Expert Opinion on Drug Safety, 2014, 13, 31-40.	2.4	9
47	No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region. Expert Opinion on Drug Safety, 2016, 15, 101-107.	2.4	9
48	Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System. Journal of Gambling Studies, 2020, 36, 85-96.	1.6	7
49	Cardiorespiratory effects of change in posture after spinal anesthesia with hyperbaric bupivacaine. Minerva Medica, 2011, 102, 501-4.	0.9	7
50	Hypoglycemia, polycythemia and hyponatremia in a newborn exposed to nebivolol during pregnancy. Journal of Pharmacology and Pharmacotherapeutics, 2015, 6, 45-48.	0.4	6
51	Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data. Pharmaceuticals, 2020, 13, 258.	3.8	6
52	Survival from coma induced by an intentional 36-g overdose of extended-release quetiapine. Drug and Chemical Toxicology, 2011, 34, 475-477.	2.3	5
53	Complete resistance after maximal dose of rocuronium. Journal of Pharmacology and Pharmacotherapeutics, 2015, 6, 175.	0.4	5
54	Contrast media-induced nephropathy: how has Italy contributed in the past 30 years? A systematic review. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1463-1478.	2.0	4

#	Article	IF	CITATIONS
55	Disclosing negative trial results – procedure. Expert Review of Clinical Pharmacology, 2016, 9, 1517-1519.	3.1	1
56	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 760-774.	1.7	1
57	SAFETY MATTERS: THE TROUBLED AND FINALLY SUCCESSFUL STORY OF DIHYDROPYRIMIDINE DEHYDROGENASE PHARMACOGENETIC TEST IN CANCER PATIENTS. , 2021, 01, 72.		O